摘要
目的:观察丹参酮ⅡA磺酸钠联合伊伐布雷定治疗急性心肌梗死(AMI)合并心力衰竭经皮冠状动脉介入(PCI)术后患者的效果。方法:回顾性分析2020年2月至2022年5月该院收治的80例AMI合并心力衰竭患者的临床资料,按照治疗方法不同将其分为观察组和对照组各40例。两组均行PCI治疗,在此基础上,对照组予以伊伐布雷定治疗,观察组在对照组基础上联合丹参酮ⅡA磺酸钠治疗,两组均连续治疗2周。比较两组临床疗效,治疗前后心功能指标[左心室射血分数(LVEF)、左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)]水平、心肌纤维化指标[结缔组织生长因子(CTGF)、可溶性ST2(sST2)、转化生长因子-β1(TGF-β1)、半乳糖凝集素-3(Gal-3)]水平,治疗期间不良反应发生率和心血管不良事件发生率。结果:观察组治疗总有效率为92.50%(37/40),高于对照组的75.00%(30/40),差异有统计学意义(P<0.05);治疗后,观察组LVEF水平高于对照组,LVEDD、LVESD、CTGF、sST2、TGF-β1、Gal-3水平均低于对照组,差异有统计学意义(P<0.05);两组治疗期间均未发生明显不良反应;两组心血管不良事件发生率比较,差异无统计学意义(P>0.05)。结论:丹参酮ⅡA磺酸钠联合伊伐布雷定治疗AMI合并心力衰竭PCI术后患者可提高治疗总有效率,改善心功能,降低心肌纤维化指标水平,效果优于单纯伊伐布雷定治疗。
Objective:To observe effects of Sodium tanshinonⅡA silate combined with Ivabradine in treatment of patients with acute myocardial infarction(AMI)complicated with heart failure after percutaneous coronary intervention(PCI).Methods:The clinical data of 80 patients with AMI complicated with heart failure admitted to this hospital from February 2020 to May 2022 were retrospectively analyzed.According to different treatment methods,they were divided into observation group and control group,40 cases in each.Both groups underwent PCI.On this basis,the control group was treated with Ivabradine,while the observation group was treated with Sodium tanshinonⅡA silate on the basis of that of the control group.Both groups were treated for 2 weeks.The clinical efficacy,the levels of cardiac function indexes[left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD)],the levels of myocardial fibrosis indexes[connective tissue growth factor(CTGF),soluble ST2(sST2),transforming growth factor-β1(TGF-β1),galectin-3(Gal-3)]before and after the treatment,the incidence of adverse reactions,and the incidence of cardiovascular adverse events during the treatment were compared between the two groups.Results:The total effective rate of treatment in the observation group was 92.50%(37/40),which was higher than 75.00%(30/40)in the control group,and the difference was statistically significant(P<0.05).After the treatment,the level of LVEF in the observation group was higher than that in the control group,the levels of LVEDD,LVESD,CTGF,sST2,TGF-β1 and Gal-3 were lower than those in the control group,and the differences were statistically significant(P<0.05).No obvious adverse reactions occurred during the treatment in the two groups.There was no significant difference in the incidence of cardiovascular adverse events between the two groups(P>0.05).Conclusions:Sodium tanshinonⅡA silate combined with Ivabradine in the treatment of the patients with AMI complicate
作者
邓帆
DENG Fan(Emergency Department of Huangchuan County People’s Hospital,Xinyang 465150 Henan,China)
出处
《中国民康医学》
2023年第16期103-106,共4页
Medical Journal of Chinese People’s Health
关键词
丹参酮ⅡA磺酸钠
伊伐布雷定
急性心肌梗死
心力衰竭
心功能
心肌纤维化
心血管不良事件
Sodium tanshinonⅡA silate
Ivabradine
Acute myocardial infarction
Heart failure
Cardiac function
Myocardial fibrosis
Cardiovascular adverse event
